glp-1 for mash Incretin-based therapies in MASLD/MASH: from receptor agonists to dual and triple agonists GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT
Description
Chaudhari DD, Singh R, Mallappa RH, Rokana N, Kaushik JK, Bajaj R, et al
Enhanced Communication with Healthcare Providers : CGMs allow you to share data with their healthcare providers, making it easier to identify patterns and adjust treatment plans
In summary, people spend substantial time in a default-mode state, during which the mind often wanders into the future
Although mechanisms underlying the BP-lowering effects of SGLT2i are unclear, SGLT2i presumably acts primarily by decreasing circulating plasma volume through osmotic and natriuretic diuresis in the early stages of administration and later by suppressing sympathetic nerve activity in the long term [8, 9]
